Aurinia Pharmaceuticals Inc. AUPH
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) is an immunology/inflammation drug developer. Its lead program, LUPKYNIS (voclosporin), is in Phase 1 for active lupus nephritis (adults).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LUPKYNIS (voclosporin) | lupus nephritis | small molecule | Approved |
| aritinercept (dual BAFF/APRIL inhibitor) | autoimmune diseases (clinical development started in four indications) | protein/peptide | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.